ArticleThe World Allergy Organization journal2018
Differences in chronic spontaneous urticaria between Europe and Central/South America: results of the multi-center real world AWARE study.
Article in The World Allergy Organization journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Evaluation of Fibromyalgia Frequency in Chronic Spontaneous Urticaria Patients Referred to a Tertiary Dermatology Outpatient Clinic.Dermatology practical & conceptual · 2026Article
- Knowledge among primary care physicians on urticaria treatment: Impact of educational interventions.The journal of allergy and clinical immunology. Global · 2026Article
- Digital Health Behavior in Chronic Spontaneous Urticaria: Internet and Social Media Use Patterns.Dermatology practical & conceptual · 2026Article
- Towards Personalised Therapy in Chronic Spontaneous Urticaria: Advancing From Endotype to Clinical Response.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025Review
- Clinical profile, prevalence, and burden of chronic spontaneous urticaria in the United States.The World Allergy Organization journal · 2025Article
- Dermatologists' knowledge, attitudes, and practices regarding omalizumab therapy for chronic urticaria.Archives of dermatological research · 2025Article
- Bridging the gap through telemedicine: Pilot study on the acceptance and use of teledermatology for urticaria.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025Article
- Cost-of-illness analysis of chronic urticaria clinical management in five countries of Latin America.Clinical and translational allergy · 2025Article
- A Practical Approach to Diagnosing and Managing Chronic Spontaneous Urticaria.Dermatology and therapy · 2024Review
- Impact of Chronic Spontaneous or Inducible Urticaria on Occupational Activity.Acta dermato-venereologica · 2024Observational
- Risk calculator of the clinical response to antihistamines in chronic urticaria: Development and internal validation.PloS one · 2024Article
- Chronic Urticaria in Older Adults: Treatment Considerations.Drugs & aging · 2023Review
- Characterization of Chronic Urticaria and Associated Conditions - A Web-Based Survey.Dermatology practical & conceptual · 2023Article
- Article
- Urticaria.Nature reviews. Disease primers · 2022Review
- Treatment Patterns and Clinical Outcomes of Chronic Urticaria: Two-year Follow-up Results from the Scandinavian AWARE Study.Acta dermato-venereologica · 2022Article
- Multicentric and Observational Study of Omalizumab for Chronic Spontaneous Urticaria in Real-Life in Colombia.Frontiers in allergy · 2022Article
- Chronic Urticaria: The Need for Improved Definition.Frontiers in allergy · 2022Article
- Comorbidities of Chronic Urticaria: A glimpse into a complex relationship.Frontiers in allergy · 2022Review
- Forewarned is forearmed: chronic spontaneous urticaria as a potential risk to effective SARS-CoV-2 vaccine uptake and global public health.The British journal of dermatology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlobal chronic urticaria (CU) disease experience and management is not well documented. This study descriptively compares these aspects among CU patients residing in Europe (EU) and Central and South America (C/SA).
methodsAWARE (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation) is a global prospective, non-interventional study of CU in the real-world setting. Patients were ≥ 18 years with a diagnosis of H1-antihistamine-refractory CU for > 2 months. Differences between the EU and C/SA regions in demographic and clinical characteristics, quality of life (QoL), work and activity impairment, pharmacological treatment, and healthcare resource use were examined.
resultsIn total, 4224 patients were included in the analysis (C/SA 492; EU 3732). Rates of untreated patients were greater in the C/SA region (45.1% vs. 31.9%;
conclusionsThis study revealed that CU is a heterogeneous condition with differences in healthcare utilization and outcomes between EU and C/SA. However, overall there is a high unmet need of H1-antihistamine-refractory CU patients, which is associated with high use of healthcare resources, and has a large negative effect on QoL and work productivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.